OMOlga N. Mironenko

Olga N. Mironenko

*This is an algorithmically generated author record based on publicly available information.

Olga N. Mironenko has a total of 267 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-term efficacy of netakimab in the treatment of radiographic axial spondyloarthritis: Results of a systematic review and simulated indirect comparisons

    by A. M. Lila, T. V. Dubinina, O. N. Mironenko, A. A. Lazarev, K. V. Sapozhnikov, K. A. Katilova, D. G. Tolkacheva, А. М. Лила, Т. В. Дубинина, О. Н. Мироненко, et al.

    The aim – to compare the long-term efficacy of netakimab with other registered drugs in the Russian Federation to treat radiographic axial spondyloarthritis over a period of up to 3 years. Materials and methods . A systematic literature search was conducted in PubMed and Embase databases. 19 publications evaluating the results of 11 clinical trials were selected. The simulated treatment comparison method according to NICE DSU TSD 18 (National Institute for Health and Care Excellence Decision Support Unit Technical Support Document 18) recommendations was used for comparison. Age, sex, BASDAI (Bath Ankylosing Spondylitis Disease Activity Index), ASDAS (Ankylosing Spondylitis Disease Activity Score), C-reactive protein, disease duration since axial spondyloarthritis diagnosis, and HLA-B27 status were selected as confounding variables for adjustment. Results . Netakimab demonstrated superiority over all interleukin 17 and tumor necrosis factor α (TNF-α) inhibitors, as well as tofacitinib, on the main efficacy endpoints ASAS20 and ASAS40 (20% and 40% improvement according to the Assessment of SpondyloArthritis international Society criteria) over a period of up to 3 years. No superiority was detected compared to upadacitinib. Conclusion. Netakimab is one of the most superior therapeutic option among available biologics for long-term treatment of active axial spondyloarthritis. Using netakimab as the first-line or second-line therapy allows achieving treatment goals with the highest probability. The results are useful for evidence-based clinical decision-making when choosing biological therapy considering patient profile and can be used for planning treatment strategy after TNF-α inhibitor failure.

  • Open Access

    Mythologization of statistics in biomedical research

    by Matvei Slavenko, Славенко Матвей Григорьевич, Olga N. Mironenko, Мироненко Ольга Николаевна, Maksim S. Kuznetsov, Кузнецов Максим Сергеевич, Evgeny A. Bakin, Бакин Евгений Александрович

    Reproducibility of scientific research has become a major concern in recent years. Inappropriate application of statistical analysis methods by researchers is considered one of the causes of the reproducibility crisis. Drawing on the concept of "statistical myths" – persistent, recurring distortions of statistical concepts – it is argued that these myths are systematic rather than accidental, serve specific functions, and reflect a deep methodological gap between the research domain and the practice of statistical analysis. The relationship between scientific and statistical inference is shown in the form of a biomedical research framework consisting of seven stages: conceptualization and formulation of the research question; operationalization; selection of the estimand; statistical model building and application; interpretation of the estimate accounting for uncertainty; clinical interpretation; and answering the research question. The framework is illustrated using examples from three real-world studies across various medical fields. Based on their functions, the authors classify statistical myths into four categories: epistemological, fundamental, instrumental, and terminological. The defining characteristics and examples of each type are provided, alongside an analysis of several widespread myths. The proposed approach allows statistical myths to be viewed not merely as a pedagogical issue, but as indicators of deeper disruptions in research logic. From a methodological perspective, rather than memorizing yet another list of "correct" and "incorrect" statistical practices, researchers are encouraged to proceed systematically from the research question at hand to its statistical formalization.

  • Comparison of 6-Year Outcomes after Open Surgery, Successful Laparoscopic Adhesiolysis, and Non-Operative Management of Adhesive Small Bowel Obstruction

    by A.E. Tyagunov, B.M. Abdulkarim, O.N. Mironenko, T.V. Nechay, I.V. Sazhin, A.A. Tyagunov, V.D. Anosov, Z.M. Alieva, N.Z. Azimova, A.V. Sazhin

    Objective. To compare short- and long-term outcomes of open surgery, laparoscopic adhesiolysis and non-operative management in patients with adhesive small bowel obstruction. Material and methods. A multiple-center retrospective cohort study included 366 patients with small bowel obstruction (SBO) treated across seven hospitals in Moscow. All patients were hospitalized between 01/01/2017 and 12/31/2019. Primary endpoints were overall survival and mean life expectancy (MLE) over 6 years after initial hospitalization, cumulative probability of rehospitalization and surgery at rehospitalization, mean duration of index hospitalization, mean duration of a single hospitalization and overall hospital-stay per a patient over 6 years. Statistical analysis included Kaplan—Meier survival analysis, Aalen—Johansen estimator, Markov modeling, Cox proportional hazards regression, log-rank test, Gray’s test, Fisher’s exact test, and Welch’s t-test. Results. At index hospitalization, non-operative management (NOM) was successful in 228 patients (62%). Open surgery (OS) was performed in 87 patients (24%) and laparoscopic adhesiolysis (LA) in 51 patients (14%). Over subsequent 6-year follow-up, 94 (26%) patients died, and 67 (19%) patients were re-hospitalized with recurrent small bowel obstruction. Of these, 17 (5%) ones underwent surgery. Over 6 years, MLE did not differ significantly between the LA and NOM groups. However, it was significantly longer compared with the OS group (by 12.7 months (95% CI: 4.2—21.2; p<0.001) and 13.8 months (95% CI: 3.7—23.8; p=0.003), respectively). The risk of SBO recurrence (rehospitalization) after NOM was higher by 5.26 times (95% CI: 1.54—16.7; p=0.004) and after OS by 3.76 times (95% CI: 1.01—13.97; p=0.046) compared to LA. Mean total hospital-stay over 6 years was significantly shorter after LA and NOM compared to OS (by 6.2 days (95% CI: 1.1—8.9; p=0.011) and 6.1 days (95% CI: 1.8—8.0; p=0.002), respectively). Cumulative probability of surgery at rehospitalization did not differ significantly (p=0.229). Conclusion. Six-year survival of patients with SBO was better after NOM and LA compared to OS. Recurrence of SBO was more common after NOM and OS.

  • Open Access

    Comparative efficacy and safety of prolgolimab and nivolumab in first-line therapy for metastatic or unresectable melanoma: a systematic review, matching-adjusted indirect comparison, and cost-effectiveness analysis

    by I. A. Utyashev, I. V. Myslevtsev, O. N. Mironenko, V. D. Batorova, K. A. Katilova, K. V. Sapozhnikov, N. A. Sableva, A. A. Lazarev, D. G. Tolkacheva

    Background . Metastatic and unresectable cutaneous melanoma (MM/uRCM) is an aggressive malignancy associated with high mortality due to its pronounced metastatic potential. Immune checkpoint inhibitors are used to treat MM/uRCM in the Russian Federation. These inhibitors include nivolumab and prolgolimab, which block the programmed cell death 1 (PD-1) receptor. However, there are no direct comparative data on their clinical and economic efficacy and safety as monotherapy, which complicates optimal therapeutic decision-making. Objective : To evaluate the clinical efficacy and safety of prolgolimab versus nivolumab in MM/uRCM treatment and to conduct cost-effectiveness analysis based on data obtained. Material and methods. A systematic literature search was conducted in the Embase and PubMed/MEDLINE databases, which identified four clinical trials of prolgolimab and nivolumab in first-line therapy for MM/uRCM. The results were used to perform a matchingadjusted indirect comparison (MAIC) without an anchor. Cox regression and logistic regression were applied for the efficacy and safety analyses, respectively. A cost minimization analysis was carried out using the weight characteristics of 743 Russian patients with MM/uRCM. The analysis only considered the costs of drug therapy. Additionally, the costs of treatment with comparator drugs were evaluated in real-world clinical setting, taking into account therapy discontinuation due to disease progression or patient death. A budget impact analysis was performed for 10 patients with MM/uRCM. Results . In MAIC, the prolgolimab monotherapy showed no statistically significant differences in overall survival compared to nivolumab after population balancing: hazard ratio (HR) 0.84 (95% confidence interval (CI) 0.47–1.50; p=0.557) in CheckMate 067 trial population; HR 0.89 (95% CI 0.53–1.49; p=0.649) in RELATIVITY-047 trial population. Similarly, for progression-free survival: HR 1.14 (95% CI 0.77–1.70; p=0.511) for CheckMate 067; HR 1.07 (95% CI 0.77–1.48; p=0.683) for RELATIVITY-047. Based on cost minimization analysis results, weighted average annual drug therapy costs for the Russian patient population were 3.98 million rubles for prolgolimab, compared to 5.33 million rubles for nivolumab (34% higher). First-year therapy costs accounting for gradual discontinuation due to progression and death were 2.39 million rubles for prolgolimab versus 3.2 million rubles for nivolumab (difference: 809,559 rubles; 34%). On a five-year horizon, total drug therapy costs were 6.16 million rubles for prolgolimab and 8.25 million rubles for nivolumab. Budget impact analysis revealed a difference in therapy costs for 10 patients with MM/uRCM over a 1-year and 5-year horizons of 13.47 and 20.84 million rubles, respectively. Due to the cost difference, an additional three patients can be treated within the analyzed timeframe. Conclusion . Prolgolimab monotherapy demonstrated no statistically significant differences in overall survival or progression-free survival compared with nivolumab in MAIC. Given its comparable clinical efficacy and lower cost per treatment course, prolgolimab is cost-effective within the Russian healthcare system and allows for increased patient coverage without additional budget expenditures.

  • Open Access

    Efficacy of neoadjuvant TCHP regimen with empegfilgrastim in early HER2-positive breast cancer: Final analysis of the DEFENDOR SPECIAL study, HER2+ BC cohort

    by Liudmila G. Zhukova, Tansylu M. Ibragimova, Daria A. Filonenko, Inna P. Ganshina, Irina V. Sorokina, Andrei A. Lazarev, Olga N. Mironenko, Oxana N. Prosianikova

    Background. The DEFENDOR SPECIAL study (NCT04905329) evaluated the efficacy and safety of combination chemotherapy with empegfilgrastim for the primary prevention of neutropenia in patients with malignancies at high risk of recurrence. This article presents the results of an investigator-initiated analysis assessing the efficacy and safety of empegfilgrastim (Extimia®) in patients with stage II–III HER2-positive breast cancer (HER2+ BC) who received neoadjuvant therapy (NAT) with the TCHP regimen. Aim. To assess the clinical efficacy and safety of prolonged granulocyte colony-stimulating factor empegfilgrastim in patients with early HER2+ BCG treated with NAT as part of the TCHP regimen. Materials and methods. Data from 105 patients were analyzed. For the primary prevention of febrile neutropenia (FN), all patients received subcutaneous empegfilgrastim at a dose of 7.5 mg once per course. The primary endpoint was the relative dose intensity of the NAT courses, and the secondary endpoints included the complete pathomorphologic regression (pCR) rate, residual cancer burden (RCB), and adverse event rate. Comparison of pCR rates in this study and in the external control group of patients with early HER2+ BC of the clinical stage cT2-cT4/cN0-cN3/cM0, who received NAT in the TCHP regimen with filgrastim for the FN prevention from April 2020 to September 2023 at the Loginov Moscow Clinical Scientific Center. The matching based on the initial characteristics was performed using complete matching with the Mahalanobis distance. Results. In the DEFENDOR SPECIAL study, the median age (Q1–Q3) was 53 (43–61) years. The median relative dose intensity (Q1–Q3) was 97.1% (76.8–104.9%). PCR was achieved in 72.5% (76/105) of patients, while RCB-I and RCB-II were observed in 6.6% (7/105) and 15.2% (16/105), respectively. The highest pCR rate was observed in patients with HR-negative/HER2-positive (3+) tumors at 85.3% (29/34). No FN events were reported. Grade III–IV neutropenia occurred in 2.9% (3/105) of patients, grade I–II thrombocytopenia in 34.3% (36/105), and grade III thrombocytopenia in 1.0% (1/105). The probability of achieving pCR with empegfilgrastim was statistically significantly higher compared to filgrastim, with an adjusted odds ratio of 1.73 (95% confidence interval 1.04–2.89; p = 0.0357). Conclusion. Primary prevention of FN with empegfilgrastim offers a significant advantage in achieving pCR compared to filgrastim in patients with early HER2-positive breast cancer receiving a neoadjuvant TCHP regimen.

  • Open Access

    Letter to the Editor Regarding the Article "Use of Autologous Dendritic Cell Vaccine CaTeVac in Melanoma Patients: Final Results of the DENDRON-01 Study"

    by Ольга Николаевна Мироненко, Игорь Вячеславович Самойленко, Ангелина Евгеньевна Ахметьянова, Алексей Александрович Румянцев, Алексей Александрович Трякин, Кирилл Викторович Сапожников, Дарья Георгиевна Токачева, Александр Валерьевич Петровский, Михаил Юрьевич Федянин

    Иммунотерапия пациентов с онкологическими заболеваниями является в настоящее время одним из наиболее перспективных направлений. При этом ее лечебные возможности выходят за пределы применения ингибиторов иммунных контрольных точек и включают клеточные технологии и противоопухолевые вакцины. Именно последним посвящена работа коллег из ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России. В данном сообщении представлен критический разбор опубликованных в журнале «Вопросы онкологии» результатов применения вакцины CaTeVac у больных меланомой в рамках исследования DENDRON-01.

  • Efficacy of immune checkpoint inhibitors in the first line therapy of non-squamous non-small cell lung cancer: A systematic review and network meta-analysis

    by Mikhail Fedyanin, Nikolai Zhukov, Fedor Moiseenko, Olga Mironenko, Kirill Sapozhnikov, Natalia Sableva, Andrei Lazarev, Daria Tolkacheva


  • Immediate and long-term treatment outcomes in patients with adhesive small bowel obstruction (recurrence rate, redo surgeries and mortality): a multiple-center study

    by A.E. Tyagunov, B.M. Abdulkarim, O.N. Mironenko, I.A. Semenenko, V.D. Anosov, V.V. Sazonov, N.S. Glagolev, Z.M. Alieva, A.V. Sazhin

    Objective. To analyze immediate and long-term outcomes of surgical and non-operative management (NOM) for adhesive small bowel obstruction (ASBO) using the Moscow Unified Medical Information and Analytical System (EMIAS). Material and methods. We retrospectively analyzed 366 patients with ASBO in 7 Moscow hospitals between January 01, 2017 and December 31, 2019. Treatment outcomes after surgery and NOM were analyzed throughout 6 years after baseline hospitalization. Results. At baseline hospitalization, mean hospital-stay for successful NOM was 6.3 (95% CI 4.3—8.2) days shorter compared to surgery (5.5±5.1 vs. 11.8±10.9 days, p<0.001). In-hospital mortality was significantly higher after surgical interventions (12.3% vs. 0.4%, p<0.001). Over a 6-year follow-up, cumulative probability of rehospitalization due to recurrent bowel obstruction was 25.8% for NOM vs. 11.6% for surgery (p=0.005). However, redo surgery rates showed no significant difference: 4.5% (NOM) vs. 5.8% (surgery). Overall survival was higher in non-operated patients (HR 1.82; 95% CI 1.21—2.72; p=0.004). Conclusion. Over a 6-year follow-up, NOM was associated with lower mortality compared to surgical intervention but higher recurrence rates of adhesive small bowel obstruction. The need for reoperation did not differ between both groups.


  • Open Access

    Comparative efficacy and safety of prolgolimab + nurulimab and nivolumab + ipilimumab in the first-line therapy of metastatic or unresectable melanoma: A systematic review and matching-adjusted indirect comparison

    by Alexander A. Fedenko, Mariya V. Sedova, Alina A. Kolomeytseva, Maxim A. Batov, Olga N. Mironenko, Kirill V. Sapozhnikov, Natalia A. Sableva, Andrey A. Lazarev, Daria G. Tolkacheva, Valentina D. Batorova, et al.

    Background. Metastatic and unresectable melanoma is considered as one of the most aggressive oncological diseases with a high mortality rate. In Russia, two first line immunotherapy combinations have been approved: nivolumab plus ipilimumab (NIVO+IPI) and prolgolimab plus nurulimab (PROLGO+NURU). Both regimens use dual immune checkpoint blockade targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). However, the lack of direct randomized comparisons between these regimens makes it difficult to choose the optimal first-line therapy. Aim. This analysis evaluated the relative efficacy and safety of PROLGO+NURU versus NIVO 1 mg/kg + IPI 3 mg/kg (NIVO 1 + IPI 3) and NIVO 3 mg/kg + IPI 1 mg/kg (NIVO 3 + IPI 1) in patients with metastatic and unresectable melanoma using matching-adjusted indirect comparisons (MAICs). Materials and methods. A systematic literature review was performed in Embase and PubMed databases. Three phase III randomized controlled trials (RCTs) were included: OCTAVA (PROLGO+NURU, n=135), CheckMate 067 (NIVO 1 mg/kg + IPI 3 mg/kg, n=314), and CheckMate 511 (two regimens: NIVO 1 mg/kg + IPI 3 mg/kg, n=178; NIVO 3 mg/kg + IPI 1 mg/kg, n=180). Individual patient data (IPD) on outcomes and baseline characteristics for PROLGO+NURU were obtained from the OCTAVA trial. For the NIVO + IPI arms, IPD on overall survival (OS) and progression-free survival (PFS) were reconstructed using Guyot’s algorithm from the published Kaplan–Meier curves, and aggregated baseline-characteristic data were extracted. Pairwise unanchored MAICs were performed, weighting on key prognostic factors and effect modifiers: baseline lactate dehydrogenase levels, TNM-defined presence of distant metastasis (M-stage), Eastern Cooperative Oncology Group (ECOG) performance status, BRAF-mutation status, PD-L1 expression 5%, age, and sum of longest diameters of target lesions. To address partial population non-overlap – specifically, the absence of mucosal melanoma and of asymptomatic central-nervous-system metastases (after local control) in OCTAVA – a simulation-based modelling was applied. Efficacy outcomes were analyzed with Cox proportional-hazards regression, and safety outcomes with logistic regression. Results. OS was statistically significantly higher in the PROLGO+NURU arm than in either NIVO 1 + IPI 3 or NIVO 3 + IPI 1 arms: hazard ratio (HR) 0.69 (95% CI 0.47–0.96; p=0.026) in the CheckMate 067 population, HR 0.64 (0.42–0.91; p=0.011) and HR 0.63 (0.41–0.89; p=0.008) – in the CheckMate 511 population versus NIVO 1 + IPI 3 and NIVO 3 + IPI 1 regimens, respectively. Differences in PFS were statistically insignificant. The PROLGO+NURU regimen also demonstrated a more favorable safety profile, with a lower incidence of treatment-related adverse events, including Grade 3–4 events and events led to treatment discontinuation. Conclusion. MAICs results showed that the PROLGO+NURU regimen achieved statistically significant superiority in OS compared with the approved NIVO+IPI regimens in Russia (as of 2025). The PROLGO+NURU combination also displayed a more favorable safety profile, with fewer treatment-related adverse events, including Grade 3–4 events and events led to treatment discontinuation. It should be emphasized that the comparison is indirect and the horizon of the comparison was limited (by about 50 months in CheckMate 511 population and 65 months in CheckMate 067 population). Consequently, the findings should be interpreted cautiously. Further updates incorporating data for the longer follow-up, including real-world data, are recommended.


  • Open Access

    Efficacy, safety, and treatment persistence of netakimab in patients with active psoriatic arthritis in real-world clinical practice: interim results of the post-marketing safety study BCD-085-NIS-03/SIRIUS

    by T. V. Korotaeva, O. A. Pritulo, O. B. Nesmeyanova, O. R. Ziganshin, L. L. Rusakova, E. S. Zhugrova, I. M. Marusenko, O. N. Mironenko

    Objective : to evaluate the efficacy, safety, and treatment persistence of netakimab (NTK) in patients with active psoriatic arthritis (PsA) in realworld clinical practice at 52 weeks of follow-up. Material and methods . This observational prospective cohort study included 149 patients with active PsA receiving NTK treatment in accordance with clinical guidelines. As of the data cut-off (April 21, 2025), the median follow-up duration was 63 weeks (range: 22–117 weeks). The primary endpoint was treatment persistence with NTK. Safety and tolerability were assessed through the documentation of adverse events (AEs). Results and discussion . By week 52, treatment persistence with NTK reached 96.0%. At the time of analysis, 12 (8.1%) out of 149 patients had discontinued NTK, with lack of efficacy reported in 9 cases. By week 52, only 2 AEs had been recorded, and just 1 was considered related to NTK. Conclusion . Over the 1-year observation period, NTK demonstrated a high treatment persistence rate, efficacy, and an acceptable safety profile in patients with PsA in real-world clinical practice.